1
|
Pena RC, Bowman MAH, Ahmad M, Pham J, Kline-Rogers E, Case MJ, Lee J, Eagle K. An Assessment of the Current Medical Management of Thoracic Aortic Disease: A Patient-Centered Scoping Literature Review. Semin Vasc Surg 2022; 35:16-34. [DOI: 10.1053/j.semvascsurg.2022.02.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/11/2022] [Accepted: 02/11/2022] [Indexed: 11/11/2022]
|
2
|
Angelov SN, Zhu J, Dichek DA. New Mouse Model of Abdominal Aortic Aneurysm: Put Out to Expand. Arterioscler Thromb Vasc Biol 2019; 37:1990-1993. [PMID: 29070538 DOI: 10.1161/atvbaha.117.310177] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Stoyan N Angelov
- From the Departments of Medicine (S.N.A., D.D.) and Surgery (J.Z.), University of Washington School of Medicine, Seattle
| | - Jay Zhu
- From the Departments of Medicine (S.N.A., D.D.) and Surgery (J.Z.), University of Washington School of Medicine, Seattle
| | - David A Dichek
- From the Departments of Medicine (S.N.A., D.D.) and Surgery (J.Z.), University of Washington School of Medicine, Seattle.
| |
Collapse
|
3
|
Enhanced endoplasmic reticulum and mitochondrial stress in abdominal aortic aneurysm. Clin Sci (Lond) 2019; 133:1421-1438. [PMID: 31239294 DOI: 10.1042/cs20190399] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 06/22/2019] [Accepted: 06/24/2019] [Indexed: 02/08/2023]
Abstract
Abdominal aortic aneurysm (AAA) is a degenerative vascular disease with a complex aetiology that remains to be fully elucidated. Clinical management of AAA is limited to surgical repair, while an effective pharmacotherapy is still awaited. Endoplasmic reticulum (ER) stress and mitochondrial dysfunction have been involved in the pathogenesis of cardiovascular diseases (CVDs), although their contribution to AAA development is uncertain. Therefore, we aimed to determine their implication in AAA and investigated the profile of oxysterols in plasma, specifically 7-ketocholesterol (7-KC), as an ER stress inducer.In the present study, we determined aortic ER stress activation in a large cohort of AAA patients compared with healthy donors. Higher gene expression of activating transcription factor (ATF) 6 (ATF6), IRE-1, X-binding protein 1 (XBP-1), C/EBP-homologous protein (CHOP), CRELD2 and suppressor/enhancer of Lin-12-like (SEL1L) and greater protein levels of active ATF6, active XBP1 and of the pro-apoptotic protein CHOP were detected in human aneurysmatic samples. This was accompanied by an exacerbated apoptosis, higher reactive oxygen species (ROS) production and by a reduction in mitochondrial biogenesis in the vascular wall of AAA. The quantification of oxysterols, performed by liquid chromatography-(atmospheric pressure chemical ionization (APCI))-mass spectrometry, showed that levels of 7-KC were significantly higher while those of 7α-hydroxycholesterol (HC), 24-HC and 27-HC were lower in AAA patients compared with healthy donors. Interestingly, the levels of 7-KC correlate with the expression of ER stress markers.Our results evidence an induction of ER stress in the vascular wall of AAA patients associated with an increase in circulating 7-KC levels and a reduction in mitochondrial biogenesis suggesting their implication in the pathophysiology of this disease.
Collapse
|
4
|
Shirasu T, Koyama H, Miura Y, Hoshina K, Kataoka K, Watanabe T. Nanoparticles Effectively Target Rapamycin Delivery to Sites of Experimental Aortic Aneurysm in Rats. PLoS One 2016; 11:e0157813. [PMID: 27336852 PMCID: PMC4919101 DOI: 10.1371/journal.pone.0157813] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 06/06/2016] [Indexed: 11/19/2022] Open
Abstract
Several drugs targeting the pathogenesis of aortic aneurysm have shown efficacy in model systems but not in clinical trials, potentially owing to the lack of targeted drug delivery. Here, we designed a novel drug delivery system using nanoparticles to target the disrupted aortic aneurysm micro-structure. We generated poly(ethylene glycol)-shelled nanoparticles incorporating rapamycin that exhibited uniform diameter and long-term stability. When injected intravenously into a rat model in which abdominal aortic aneurysm (AAA) had been induced by infusing elastase, labeled rapamycin nanoparticles specifically accumulated in the AAA. Microscopic analysis revealed that rapamycin nanoparticles were mainly distributed in the media and adventitia where the wall structures were damaged. Co-localization of rapamycin nanoparticles with macrophages was also noted. Rapamycin nanoparticles injected during the process of AAA formation evinced significant suppression of AAA formation and mural inflammation at 7 days after elastase infusion, as compared with rapamycin treatment alone. Correspondingly, the activities of matrix metalloproteinases and the expression of inflammatory cytokines were significantly suppressed by rapamycin nanoparticle treatment. Our findings suggest that the nanoparticle-based delivery system achieves specific delivery of rapamycin to the rat AAA and might contribute to establishing a drug therapy approach targeting aortic aneurysm.
Collapse
Affiliation(s)
- Takuro Shirasu
- Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Hiroyuki Koyama
- Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Translational Research Center, The University of Tokyo Hospital, Tokyo, Japan
- Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
- * E-mail:
| | - Yutaka Miura
- Departments of Materials Engineering and Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
- Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Katsuyuki Hoshina
- Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Kazunori Kataoka
- Departments of Materials Engineering and Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
- Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Toshiaki Watanabe
- Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
5
|
Galán M, Varona S, Orriols M, Rodríguez JA, Aguiló S, Dilmé J, Camacho M, Martínez-González J, Rodriguez C. Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors. Dis Model Mech 2016; 9:541-52. [PMID: 26989193 PMCID: PMC4892665 DOI: 10.1242/dmm.024513] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 03/14/2016] [Indexed: 02/01/2023] Open
Abstract
Clinical management of abdominal aortic aneurysm (AAA) is currently limited to elective surgical repair because an effective pharmacotherapy is still awaited. Inhibition of histone deacetylase (HDAC) activity could be a promising therapeutic option in cardiovascular diseases. We aimed to characterise HDAC expression in human AAA and to evaluate the therapeutic potential of class I and IIa HDAC inhibitors in the AAA model of angiotensin II (Ang II)-infused apolipoprotein-E-deficient (ApoE−/−) mice. Real-time PCR, western blot and immunohistochemistry evidenced an increased expression of HDACs 1, 2 (both class I), 4 and 7 (both class IIa) in abdominal aorta samples from patients undergoing AAA open repair (n=22) compared with those from donors (n=14). Aortic aneurysms from Ang-II-infused ApoE−/− mice exhibited a similar HDAC expression profile. In these animals, treatment with a class I HDAC inhibitor (MS-275) or a class IIa inhibitor (MC-1568) improved survival, reduced the incidence and severity of AAA and limited aneurysmal expansion evaluated by Doppler ultrasonography. These beneficial effects were more potent in MC-1568-treated mice. The disorganisation of elastin and collagen fibres and lymphocyte and macrophage infiltration were effectively reduced by both inhibitors. Additionally, HDAC inhibition attenuated the exacerbated expression of pro-inflammatory markers and the increase in metalloproteinase-2 and -9 activity induced by Ang II in this model. Therefore, our data evidence that HDAC expression is deregulated in human AAA and that class-selective HDAC inhibitors limit aneurysm expansion in an AAA mouse model. New-generation HDAC inhibitors represent a promising therapeutic approach to overcome human aneurysm progression. Summary: This study reports the upregulation of HDACs in human AAA, evidences that HDAC inhibitors limit aneurysm progression in a preclinical model and suggests the therapeutic interest of HDAC inhibition in AAA.
Collapse
Affiliation(s)
- María Galán
- Centro de Investigación Cardiovascular (CSIC-ICCC), Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| | - Saray Varona
- Centro de Investigación Cardiovascular (CSIC-ICCC), Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| | - Mar Orriols
- Centro de Investigación Cardiovascular (CSIC-ICCC), Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| | - José Antonio Rodríguez
- Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain
| | - Silvia Aguiló
- Centro de Investigación Cardiovascular (CSIC-ICCC), Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| | - Jaume Dilmé
- Laboratorio de Angiología, Biología Vascular e Inflamación y Servicio de Cirugía Vascular, Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| | - Mercedes Camacho
- Laboratorio de Angiología, Biología Vascular e Inflamación y Servicio de Cirugía Vascular, Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| | - José Martínez-González
- Centro de Investigación Cardiovascular (CSIC-ICCC), Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| | - Cristina Rodriguez
- Centro de Investigación Cardiovascular (CSIC-ICCC), Instituto de Investigación Biomédica (IIB-Sant Pau), 08025 Barcelona, Spain
| |
Collapse
|
6
|
Kroon AM, Taanman JW. Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice? Int J Mol Sci 2015; 16:11178-95. [PMID: 25993290 PMCID: PMC4463695 DOI: 10.3390/ijms160511178] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Accepted: 02/05/2015] [Indexed: 11/16/2022] Open
Abstract
Most reported studies with animal models of abdominal aortic aneurysm (AAA) and several studies with patients have suggested that doxycycline favourably modifies AAA; however, a recent large long-term clinical trial found that doxycycline did not limit aneurysm growth. Thus, there is currently no convincing evidence that doxycycline reduces AAA expansion. Here, we critically review the available experimental and clinical information about the effects of doxycycline when used as a pharmacological treatment for AAA. The view that AAA can be considered an autoimmune disease and the observation that AAA tissue shows clonal expansion of T cells is placed in the light of the well-known inhibition of mitochondrial protein synthesis by doxycycline. In T cell leukaemia animal models, this inhibitory effect of the antibiotic has been shown to impede T cell proliferation, resulting in complete tumour eradication. We suggest that the available evidence of doxycycline action on AAA is erroneously ascribed to its inhibition of matrix metalloproteinases (MMPs) by competitive binding of the zinc ion co-factor. Although competitive binding may explain the inhibition of proteolytic activity, it does not explain the observed decreases of MMP mRNA levels. We propose that the observed effects of doxycycline are secondary to inhibition of mitochondrial protein synthesis. Provided that serum doxycycline levels are kept at adequate levels, the inhibition will result in a proliferation arrest, especially of clonally expanding T cells. This, in turn, leads to the decrease of proinflammatory cytokines that are normally generated by these cells. The drastic change in cell type composition may explain the changes in MMP mRNA and protein levels in the tissue samples.
Collapse
Affiliation(s)
- Albert M Kroon
- Department of Clinical Neurosciences, Institute of Neurology, University College London, London NW3 2PF, UK.
| | - Jan-Willem Taanman
- Department of Clinical Neurosciences, Institute of Neurology, University College London, London NW3 2PF, UK.
| |
Collapse
|
7
|
Bhamidipati CM, Whatling CA, Mehta GS, Meher AK, Hajzus VA, Su G, Salmon M, Upchurch GR, Owens GK, Ailawadi G. 5-Lipoxygenase pathway in experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2014; 34:2669-78. [PMID: 25324573 PMCID: PMC4239157 DOI: 10.1161/atvbaha.114.304016] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
OBJECTIVE The impact of leukotriene production by the 5-lipoxygenase (5-LO) pathway in the pathophysiology of abdominal aortic aneurysms (AAAs) has been debated. Moreover, a clear mechanism through which 5-LO influences AAA remains unclear. APPROACH AND RESULTS Aneurysm formation was attenuated in 5-LO(-/-) mice, and in lethally irradiated wild-type mice reconstituted with 5-LO(-/-) bone marrow in an elastase perfusion model. Pharmacological inhibition of 5-LO-attenuated aneurysm formation in both aortic elastase perfused wild-type and angiotensin II-treated LDLr(-/-) (low-density lipoprotein receptor) mice, with resultant preservation of elastin and fewer 5-LO and MMP9 (matrix metalloproteinase)-producing cells. Separately, analysis of wild-type mice 7 days after elastase perfusion showed that 5-LO inhibition was associated with reduced polymorphonuclear leukocyte infiltration to the aortic wall. Importantly, 5-LO inhibition initiated 3 days after elastase perfusion in wild-type mice arrested progression of small AAA. Human AAA and control aorta corroborated these elastin and 5-LO expression patterns. CONCLUSIONS Inhibition of 5-LO by pharmacological or genetic approaches attenuates aneurysm formation and prevents fragmentation of the medial layer in 2 unique AAA models. Administration of 5-LO inhibitor in small AAA slows progression of AAA. Targeted interruption of the 5-LO pathway is a potential treatment strategy in AAA.
Collapse
MESH Headings
- Aged
- Angiotensin II/metabolism
- Animals
- Aorta, Abdominal/drug effects
- Aorta, Abdominal/enzymology
- Aorta, Abdominal/pathology
- Aortic Aneurysm, Abdominal/enzymology
- Aortic Aneurysm, Abdominal/etiology
- Aortic Aneurysm, Abdominal/pathology
- Arachidonate 5-Lipoxygenase/deficiency
- Arachidonate 5-Lipoxygenase/genetics
- Arachidonate 5-Lipoxygenase/metabolism
- Bone Marrow Transplantation
- Disease Models, Animal
- Disease Progression
- Humans
- Hypercholesterolemia/complications
- Hypercholesterolemia/enzymology
- Lipoxygenase Inhibitors/pharmacology
- Male
- Matrix Metalloproteinase 9/biosynthesis
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Middle Aged
- Neutrophil Infiltration
- Pancreatic Elastase/metabolism
- Receptors, LDL/deficiency
- Receptors, LDL/genetics
- Signal Transduction
- Transplantation Chimera/metabolism
Collapse
Affiliation(s)
- Castigliano M Bhamidipati
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Carl A Whatling
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Gaurav S Mehta
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Akshaya K Meher
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Vanessa A Hajzus
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Gang Su
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Morgan Salmon
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Gilbert R Upchurch
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Gary K Owens
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.)
| | - Gorav Ailawadi
- From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (C.M.B., A.K.M., V.A.H., G.A.), Department of Surgery (G.S.M.), Division of Vascular and Endovascular Surgery, Department of Surgery (G.S., G.R.U.), Department of Molecular Physiology and Biological Physics (M.S., G.K.O.), Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center (G.R.U., G.K.O., G.A.), and Department of Biomedical Engineering (G.A.), University of Virginia School of Medicine, Charlottesville; and Cardiovascular Disease Section, Bioscience Department, AstraZeneca R&D, Mölndal, Sweden (C.A.W.).
| |
Collapse
|
8
|
Thatcher SE, Zhang X, Howatt DA, Yiannikouris F, Gurley SB, Ennis T, Curci JA, Daugherty A, Cassis LA. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2014; 34:2617-23. [PMID: 25301841 DOI: 10.1161/atvbaha.114.304613] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Angiotensin-converting enzyme 2 (ACE2) cleaves angiotensin II (AngII) to form angiotensin-(1-7) (Ang-(1-7)), which generally opposes effects of AngII. AngII infusion into hypercholesterolemic male mice induces formation of abdominal aortic aneurysms (AAAs). This study tests the hypothesis that deficiency of ACE2 promotes AngII-induced AAAs, whereas ACE2 activation suppresses aneurysm formation. APPROACH AND RESULTS ACE2 protein was detectable by immunostaining in mice and human AAAs. Whole-body deficiency of ACE2 significantly increased aortic lumen diameters and external diameters of suprarenal aortas from AngII-infused mice. Conversely, ACE2 deficiency in bone marrow-derived cells had no effect on AngII-induced AAAs. In contrast to AngII-induced AAAs, ACE2 deficiency had no significant effect on external aortic diameters of elastase-induced AAAs. Because ACE2 deficiency promoted AAA formation in AngII-infused mice, we determined whether ACE2 activation suppressed AAAs. ACE2 activation by administration of diminazene aceturate (30 mg/kg per day) to Ldlr(-/-) mice increased kidney ACE2 mRNA abundance and activity and elevated plasma Ang-(1-7) concentrations. Unexpectedly, administration of diminazene aceturate significantly reduced total sera cholesterol and very low-density lipoprotein-cholesterol concentrations. Notably, diminazene aceturate significantly decreased aortic lumen diameters and aortic external diameters of AngII-infused mice resulting in a marked reduction in AAA incidence (from 73% to 29%). None of these effects of diminazene aceturate were observed in the Ace2(-/y) mice. CONCLUSIONS These results demonstrate that ACE2 exerts a modulatory role in AngII-induced AAA formation, and that therapeutic stimulation of ACE2 could be a benefit to reduce AAA expansion and rupture in patients with an activated renin-angiotensin system.
Collapse
Affiliation(s)
- Sean E Thatcher
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - Xuan Zhang
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - Deborah A Howatt
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - Frederique Yiannikouris
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - Susan B Gurley
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - Terri Ennis
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - John A Curci
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - Alan Daugherty
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.)
| | - Lisa A Cassis
- From the Department of Pharmacology and Nutritional Sciences (S.E.T., F.Y., L.A.C.), Graduate Center for Toxicology (X.Z.), and Saha Cardiovascular Research Center, Department of Internal Medicine (D.A.H., A.D.), University of Kentucky, Lexington; Division of Nephrology, Department of Medicine, Duke University, Durham, NC (S.B.G.); and Department of Surgery, Section of Vascular Surgery, Washington University, St Louis, MO (T.E., J.A.C.).
| |
Collapse
|
9
|
Tharappel JC, Bower CE, Whittington Harris J, Ramineni SK, Puleo DA, Roth JS. Doxycycline administration improves fascial interface in hernia repair. J Surg Res 2014; 190:692-8. [DOI: 10.1016/j.jss.2014.05.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Revised: 04/23/2014] [Accepted: 05/02/2014] [Indexed: 02/01/2023]
|